'Demonised' drink actually has healthy benefits
That's despite a lot of critics saying that coffee can be detrimental to your heart rate and blood pressure in the short term. But the professor of genetic epidemiology at King's College London championed its benefits, reports GloucestershireLive.
Professor Spector is also the co-founder of the health app Zoe. He spoke of the potential benefits whilst on a podcast with coffee expert James Hoffman.
READ MORE: BBC Strictly Come Dancing star praised for 'real' Instagram post as fans share support
Get breaking news on BirminghamLive WhatsApp, click the link to join
The scientist explained that there are essential nutrients packed in coffee, which also has a surprising amount of five. And studies have also shown that it could reduce heart attack risks by 25%.
And Prof Spector added that he is working on a scientific paper on coffee and the gut microbiome, and how interactions between the two can reduce our blood pressure and blood sugar. Watch the full discussion here.
He said: 'What are the health benefits? One of the key things in coffee. It's a complex area, but I think we're suddenly putting it together from a drink that was demonised as being very harmful to us to something that actually could be beneficial. Coffee is this fermented plant that has microbes acting on.
'It has hundreds, not thousands, of chemicals produced from it. There's range of polyphenols that are enhanced by the microbes as they ferment it. And those have direct effects on our body, and some of them can reduce blood sugar and reduce stress and actually reduce blood pressure. And the studies have now clearly shown that you get nearly as much benefit on the heart with decaffeinated coffee.'
Speaking previously in a health Q&A on his Instagram page, Prof Spector answered a number of questions about healthy eating and drinking - including how much coffee is healthy, eating breads and how to find and eat cheap vegetables and fruits. His answer on coffee is perhaps the most surprising - because he suggests people should have lots of it.
He said: 'Coffee is a health food, and we should all be drinking at least three cups a day, according to the latest science. And it doesn't matter if you don't want caffeine, just have decaf. It's probably just as healthy.
'In fact studies have shown that moderate coffee intake—about 2–5 cups a day—is linked to a lower likelihood of type 2 diabetes, heart disease, liver and endometrial cancers, Parkinson's disease, and depression. It's even possible that people who drink coffee can reduce their risk of early death.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
Yahoo
38 minutes ago
- Yahoo
Construction workers break ground on first-of-its-kind nuclear facility: 'The most significant development'
Across the world, investment in renewable energy is evident. Now, advances in Romania are pushing the needle closer to a clean energy future. According to Romania Insider, construction of Europe's very first tritium removal facility began in early June 2025. This would put the facility in a great position for future nuclear fusion processes. The work is happening at a nuclear power plant in Cernavodă and was called "the most significant development in Romania's nuclear sector since the commissioning of Cernavodă's Unit 2 reactor" by Sebastian Burduja, the Minister of Energy in Romania, according to Romania Insider. In simple terms, nuclear energy works by harnessing the energy contained in an atom's nucleus — either by splitting the atom (in nuclear fission) or by combining atoms (in nuclear fusion). "Nuclear fusion is the process by which two light atomic nuclei combine to form a single heavier one while releasing massive amounts of energy," the International Atomic Energy Agency has stated. By removing tritium from the water used in existing nuclear fission reactors, the water can, in turn, be reused, and the tritium stored for fuel in future nuclear fusion reactors — as Romania Insider explained. This process conserves two vital resources at once. "This project positions Romania among the few countries capable of producing and exporting tritium — seen as the fuel of the future for fusion energy programs …" Energy Minister Burduja said to the news outlet. Nuclear energy is the largest source of "clean energy" in the U.S, according to the Department of Energy (defining it as clean energy because it produces almost no carbon pollution). It can supply energy on demand — unlike wind and solar, which rely on the weather or time of day — making the move away from dirty fuel sources more seamless. Nuclear fission, which generates electricity today, does create radioactive waste and has a history of uncommon but significant disasters. By comparison, nuclear fusion, which is still in development for producing electricity, has advantages that include not creating long-lived radioactive waste while producing abundant clean energy. Investing in renewable energy for your home is another way to tap into the benefits of pollution-free energy — such as cleaner air, a smaller carbon footprint, and cheaper utility bills. A straightforward way of doing this is the installation of rooftop solar panels. Should we be pouring money into nuclear fusion technology? Yes — it'll pay off It's worth exploring Not from our tax dollars No — it's a waste Click your choice to see results and speak your mind. Not only can these panels bring your personal electric bill down to at or near $0 a month, but they also don't release the toxic, heat-trapping fumes that are produced by power plants that rely on coal, gas, or oil. EnergySage provides a free service that makes it easy to compare quotes from vetted local installers and save up to $10,000 on your new solar installations. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Associated Press
44 minutes ago
- Associated Press
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading 'Principal Risks and Uncertainties' in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
